Page 105 - Read Online

Falconer et al. MT-MMPs in prostate cancer

30. Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S. factor receptor 4 stability promotes prostate cancer progression.
Membrane type 1 matrix metalloproteinase induces epithelial- Neoplasia 2008;10:847-56.
to-mesenchymal transition in prostate cancer. J Biol Chem 47. Sugiyama N, Varjosalo M, Meller P, Lohi J, Hyytiainen M, Kilpinen
2008;283:6232-40. S, Kallioniemi O, Ingvarsen S, Engelholm LH, Taipale J, Alitalo K,
31. Dissanayake SK, Wade M, Johnson CE, O’Connell MP, Leotlela PD, Keski-Oja J, Lehti K. Fibroblast growth factor receptor 4 regulates
French AD, Shah KV, Hewitt KJ, Rosenthal DT, Indig FE, Jiang Y, tumor invasion by coupling fibroblast growth factor signaling to
Nickoloff BJ, Taub DD, Trent JM, Moon RT, Bittner M, Weeraratna extracellular matrix degradation. Cancer Res 2010;70:7851-61.
AT. The Wnt5A/protein kinase C pathway mediates motility in 48. Nguyen HL, Zucker S, Zarrabi K, Kadam P, Schmidt C, Cao J.
melanoma cells via the inhibition of metastasis suppressors and Oxidative stress and prostate cancer progression are elicited by
initiation of an epithelial to mesenchymal transition. J Biol Chem membrane-type 1 matrix metalloproteinase. Mol Cancer Res
2007;282:17259-71. 2011;9:1305-18.
32. Bair EL, Chen ML, McDaniel K, Sekiguchi K, Cress AE, Nagle 49. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN
RB, Bowden GT. Membrane type 1 matrix metalloprotease cleaves loss associated with clinical outcome measures in human prostate
laminin-10 and promotes prostate cancer cell migration. Neoplasia cancer? Br J Cancer 2008;99:1296-301.
2005;7:380-9. 50. Kim S, Huang W, Mottillo EP, Sohail A, Ham YA, Conley-
33. Udayakumar TS, Chen ML, Bair EL, Von Bredow DC, Cress AE, Lacomb MK, Kim CJ, Tzivion G, Kim HR, Wang S, Chen YQ,
Nagle RB, Bowden GT. Membrane type-1-matrix metalloproteinase Fridman R. Posttranslational regulation of membrane type 1-matrix
expressed by prostate carcinoma cells cleaves human laminin-5 beta3 metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer
chain and induces cell migration. Cancer Res 2003;63:2292-9. cells: enhanced surface expression and differential O-glycosylation of
34. Wang X, Wilson MJ, Slaton JW, Sinha AA, Ewing SL, Pei D. Increased MT1-MMP. Biochim Biophys Acta 2010;1803:1287-97.
aggressiveness of human prostate PC-3 tumor cells expressing cell 51. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated
surface localized membrane type-1 matrix metalloproteinase (MT1- translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
MMP). J Androl 2009;30:259-74. 52. Lin HY, Amankwah EK, Tseng TS, Qu X, Chen DT, Park JY. SNP-
35. Kogianni G, Walker MM, Waxman J, Sturge J. Endo180 expression SNP interaction network in angiogenesis genes associated with
with cofunctional partners MT1-MMP and uPAR-uPA is correlated prostate cancer aggressiveness. PLoS One 2013;8:e59688.
with prostate cancer progression. Eur J Cancer 2009;45:685-93. 53. Parray A, Siddique HR, Kuriger JK, Mishra SK, Rhim JS, Nelson
36. Wang Y, Zhang YX, Kong CZ, Zhang Z, Zhu YY. Loss of P53 HH, Aburatani H, Konety BR, Koochekpour S, Saleem M. ROBO1,
facilitates invasion and metastasis of prostate cancer cells. Mol Cell a tumor suppressor and critical molecular barrier for localized tumor
Biochem 2013;384:121-7. cells to acquire invasive phenotype: study in African-American and
Caucasian prostate cancer models. Int J Cancer 2014;135:2493-506.
37. Sankpal UT, Goodison S, Abdelrahim M, Basha R. Targeting Sp1 54. Di Lorenzo G, Tortora G, D’Armiento FP, De Rosa G, Staibano S,
transcription factors in prostate cancer therapy. Med Chem 2011;7:518-
25. Autorino R, D’Armiento M, De Laurentiis M, De Placido S, Catalano
G, Bianco AR, Ciardiello F. Expression of epidermal growth factor
38. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor correlates with disease relapse and progression to androgen-
receptor signalling in cancer. Br J Cancer 2005;92:2097-101. independence in human prostate cancer. Clin Cancer Res 2002;8:3438-
39. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, 44.
Kitaura Y, Takai S, Sasahara RM, Horimoto A, Ikawa Y, Ratzkin BJ, 55. Lin HY, Chen DT, Huang PY, Liu YH, Ochoa A, Zabaleta J, Mercante
Arakawa T, Noda M. Regulation of matrix metalloproteinase-9 and DE, Fang Z, Sellers TA, Pow-Sang JM, Cheng CH, Eeles R, Easton
inhibition of tumor invasion by the membrane-anchored glycoprotein D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG,
RECK. Proc Natl Acad Sci U S A 1998;95:13221-6. Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG,
40. Miki T, Takegami Y, Okawa K, Muraguchi T, Noda M, Takahashi Travis RC, Hamdy F, Pashayan N, Khaw KT, Stanford JL, Blot WJ,
C. The reversion-inducing cysteine-rich protein with Kazal motifs Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright
(RECK) interacts with membrane type 1 matrix metalloproteinase and L, Brenner H, Kaneva R, Batra J, Teixeira MR, Pandha H, Lu YJ,
CD13/aminopeptidase N and modulates their endocytic pathways. J Consortium P, Park JY. SNP interaction pattern identifier (SIPI): an
Biol Chem 2007;282:12341-52. intensive search for SNP-SNP interaction patterns. Bioinformatics
41. Rabien A, Ergun B, Erbersdobler A, Jung K, Stephan C. RECK 2017;33:822-33.
overexpression decreases invasive potential in prostate cancer cells. 56. Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann
Prostate 2012;72:948-54. J, Trudeau V, Graefen M, Montorsi F, Sun M. Impact of the site of
42. Filiz G, Dass CR. Reduction in tumour cell invasion by pigment metastases on survival in patients with metastatic prostate cancer. Eur
epithelium-derived factor is mediated by membrane type-1 matrix Urol 2015;68:325-34.
metalloproteinase downregulation. Pharmazie 2012;67:1010-4. 57. Manca P, Pantano F, Iuliani M, Ribelli G, De Lisi D, Danesi R, Del
43. Qingyi Z, Lin Y, Junhong W, Jian S, Weizhou H, Long M, Zeyu S, Re M, Vincenzi B, Tonini G, Santini D. Determinants of bone specific
Xiaojian G. Unfavorable prognostic value of human PEDF decreased metastasis in prostate cancer. Crit Rev Oncol Hematol 2017;112:59-66.
in high-grade prostatic intraepithelial neoplasia: a differential 58. Bonfil RD, Fridman R, Mobashery S, Cher ML. Are matrix
proteomics approach. Cancer Invest 2009;27:794-801. metalloproteinases relevant therapeutic targets for prostate cancer
44. Tapia T, Ottman R, Chakrabarti R. LIM kinase1 modulates function of bone metastasis? Curr Oncol 2008;15:188-92.
membrane type matrix metalloproteinase 1: implication in invasion of 59. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov
prostate cancer cells. Mol Cancer 2011;10:6. SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-
45. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia,
Gnanapragasam VJ. Selective over-expression of fibroblast arthritis, and connective tissue disease due to inadequate collagen
growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol turnover. Cell 1999;99:81-92.
2007;213:82-90. 60. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B,
46. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth Bhagat S, Mullins C, Fridman R, Cher ML. Matrix metalloproteinase

326 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 12, 2017